-
-
-
-
-
-
-
Goldman Sachs on uniQure BV (QURE): 'we now expect a US approval in 2Q27 (vs. 2030 prior, assuming priority review...'
-
-
-
-
-
-
-
uniQure plans BLA submission for Huntington's therapy in Q3 2026
-
-
-
-
-
-
-
Mizuho's Jared Holz: 'We still like the sector, despite some recent setbacks like QURE and others'
-
-
-
-
-
-
-
uniQure BV (QURE) PT Lowered to $35 at Leerink Partners
-
-
-
-
-
-
-
Stifel: 'We can see why QURE shares are lower on CNBC comments from FDA'
-
-
-
-
-
-
-
uniQure (QURE) Reiterated at Overweight by Cantor Fitzgerald: FDA Feedback Key
-
-
-
-
-
-
-
uniQure BV (QURE) PT Lowered to $60 at Leerink Partners
-
434,572 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

